Condition: Influenza · Sponsor: Aramis Biotechnologies Inc.
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
This description comes directly from the study's public registry record.
Sonia Trepanier, Ph.D. · Canada: 1-418-655-7158 · Strepanier@aramisbiotechnologies.com
Sebastien Soucy · Canada: 1-418-446-2032 · ssoucy@aramisbiotechnologies.com
Always discuss trial participation with your own doctor first.
| Canadian Center for Vaccinology (CCfV) - IWK Health | Halifax, Nova Scotia, Canada | Recruiting |
| Montreal Heart Institute | Montreal, Quebec, Canada | Recruiting |
| Vaccine Study Centre of McGill University Health Centre | Pierrefonds, Quebec, Canada | Recruiting |
| CHU de Québec - Université Laval | Québec, Quebec, Canada | Recruiting |
| Diex Recherche - Sherbrooke | Sherbrooke, Quebec, Canada | Recruiting |
| Diex Recherche - Trois-Rivières | Trois-Rivières, Quebec, Canada | Recruiting |
| Diex Recherche - Victoriaville | Victoriaville, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07291635